Effects of cisapride on QTC interval in neonates

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 77, Issue 3, 1997, Pages

  Bernardini, S ^a,b   Semama, D S ^a,b   Huet, F ^a,b   Sgro, C ^c   Gouyon, J B ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Hopital d'Enfants   (Morocco)

^c Ctr Reg de Pharmacovigilance

Author keywords

Cisapride; QT interval; QTc interval

Indexed keywords

CISAPRIDE;

ARTICLE; AUDIOMETRY; CALCULATION; CASE REPORT; DOSE RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; MALE; NEWBORN; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT PLANNING;

EID: 0031409542     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.77.3.F241     Document Type: Article

References (18)

1. Melis K, Janssens G. Long term use of cisapride (Prepulsid®) in premature neonates. Acta Gastroenterol Belg 1990;53:372-5.
2. Janssens G, Melis K, Vaerenberg M. Long term use of cisapride (Prepulsid®) in premature neonates of less 34 weeks gestational age. J Pediatr Gastroenterol Nutr 1990;11:420-5.
3. Wiseman LR, Faulds D. Cisapride. An update review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-52.
4. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high dose cisapride. Arch Intern Med 1995;155:765-8.
5. Ahmad SR, Wolfe SM. Cisapride and torsades de pointes. Lancet 1995;345:508.
6. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride-induced long QT interval. J Pediatr 1996;128:279-81.
7. Tan HL, Hou CJY, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995;122:701-14.
8. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991;5:515-30.
9. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-1.
10. Schwartz PJ, Montemerlo M, Facchini M, et al. The QT interval throughout the first six months of life: A prospective study. Circulation 1982;66:496-501.
11. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992;305:748-9.
12. Usha Rani P, Naidu MUR, Ramesh-Kumar T, Shobha JC, Kumar A. Tachycardia during cisapride treatment. Indian J Pharmacol 1994;26:233-4.
13. Woodard-Jenkins J, Woolf A. Spectrum of toxicity seen in cisapride poisoning. J Toxicol 1995;33:490A.
14. Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996;117:1377-9.
15. Smith Rogers A. The role of cytochrome P450 in developmental pharmacology. J Adolesc Health 1994;15:635-40.
16. Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Interaction of triazolam and ketoconazole. Lancet 1995;345:191.
17. Ervine CM, Matthew DE, Brennan B, Housyon JB. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Drug Metab Dispos 1996;24:211-15.
18. Boehm G, Teichmann B, Krumbiegel P. Heparic biotransformation capacity in low-birth-weight infants as measured with the [15N]Methacetin urine test: Influences of gestational age, postnatal age, and intrauterine growth retardation. Biol Neonate 1995;68:19-25.